Paper39796708
Molecular Basis of Oncogenic PI3K Proteins.
Sheng Z and 4 others. Cancers (Basel), 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Molecular Basis of Oncogenic PI3K Proteins. Papers, record 39796708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796708
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21 CA245631 | NCI NIH HHS | United States | R21CA245631 | PubMed | NIH RePORTER |
| R21 CA289124 | NCI NIH HHS | United States | R21CA289124 | PubMed | NIH RePORTER |
| R21CA289124 | NCI NIH HHS | United States | R21CA289124 | PubMed | NIH RePORTER |
| R21CA245631 | NCI NIH HHS | United States | R21CA245631 | PubMed | NIH RePORTER |
References166
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28630349 | PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28630349 | PubMed |
| 2 | 19915146 | Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19915146 | PubMed |
| 3 | 11090628 | Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. | Mol Cell | 2000 | https://conductscience.org/library/papers/11090628 | PubMed |
| 4 | 28676499 | Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. | J Biol Chem | 2017 | https://conductscience.org/library/papers/28676499 | PubMed |
| 5 | 1849460 | cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. | Cell | 1991 | https://conductscience.org/library/papers/1849460 | PubMed |
| 6 | 10196176 | Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. | J Biol Chem | 1999 | https://conductscience.org/library/papers/10196176 | PubMed |
| 7 | 38565696 | Molecular basis for Gβγ-mediated activation of phosphoinositide 3-kinase γ. | Nat Struct Mol Biol | 2024 | https://conductscience.org/library/papers/38565696 | PubMed |
| 8 | 31135801 | The structural basis for Ras activation of PI3Kα lipid kinase. | Phys Chem Chem Phys | 2019 | https://conductscience.org/library/papers/31135801 | PubMed |
| 9 | 25533673 | PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. | Nat Rev Cancer | 2015 | https://conductscience.org/library/papers/25533673 | PubMed |
| 10 | 35022385 | Connexin 43 confers chemoresistance through activating PI3K. | Oncogenesis | 2022 | https://conductscience.org/library/papers/35022385 | PubMed |
| 11 | 24459181 | The structural basis of PI3K cancer mutations: from mechanism to therapy. | Cancer Res | 2014 | https://conductscience.org/library/papers/24459181 | PubMed |
| 12 | 25284480 | Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25284480 | PubMed |
| 13 | 18544649 | The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18544649 | PubMed |
| 14 | 25956158 | Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies. | Mol Cancer Res | 2015 | https://conductscience.org/library/papers/25956158 | PubMed |
| 15 | 37623743 | STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts. | Cancer Discov | 2023 | https://conductscience.org/library/papers/37623743 | PubMed |
| 16 | 36243839 | An Overview of Class II Phosphoinositide 3-Kinases. | Curr Top Microbiol Immunol | 2022 | https://conductscience.org/library/papers/36243839 | PubMed |
| 17 | 11136978 | Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. | Cell | 2000 | https://conductscience.org/library/papers/11136978 | PubMed |
| 18 | 25187123 | Idelalisib: first global approval. | Drugs | 2014 | https://conductscience.org/library/papers/25187123 | PubMed |
| 19 | 9182708 | Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin. | Biochem J | 1997 | https://conductscience.org/library/papers/9182708 | PubMed |
| 20 | 16432180 | Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16432180 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42764855 | Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42764855 | PubMed |
| 42738319 | PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738319 | PubMed |
| 42621358 | Oncometabolites in Cancer Metabolism: Mechanistic Insights and Biomarker Potential- A Narrative Review. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42621358 | PubMed |
| 41754736 | The PI3K/AKT/NRF2 Signaling Pathway Involved in the Improvement of CUMS-Induced Depressive-like Behaviors by Apigenin. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41754736 | PubMed |
| 41239272 | Anoikis resistance and cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41239272 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PIK3R1 | 5295 | PubTator's text mining | https://conductscience.org/library/genes/5295 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796708
GET https://conductscience.org/api/papers/v1/39796708/references?page=2